Apart from using PRL3-zumab to treat PRL3-positive tumors, in this report, we proposed PRL3-zumab could serve in another critical usage as an ‘Adjuvant immunotherapy’ immediately after patient’s tumor removal to clean up PRL3+ PGCC stem-like cells. This evidence concerns the gene PTP4A3 and neoplasm.